ALK polypeptides and methods of use thereof

Abstract

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

Other embodiments are described in the following claims: 
     
       1. An amphiphilic conjugate comprising:
 (a) an albumin-binding domain; 
 (b) an ALK polypeptide; and 
 (c) an optional linker, 
 wherein the ALK polypeptide is 9 to 40 amino acids in length, comprises at least Z contiguous amino acids from the sequence of SEQ ID NO:23, and does not comprise a sequence of any one of SEQ ID NOs: 67-70 and 140-145, and 
 wherein the ALK polypeptide is conjugated directly to the albumin-binding domain or is conjugated to the albumin-binding domain through the linker. 
 
     
     
       2. The amphiphilic conjugate of  claim 1 , wherein the albumin-binding domain is a lipid. 
     
     
       3. The amphiphilic conjugate of  claim 1 , wherein the linker is selected from the group consisting of polymers, a string of amino acids, nucleic acids, polysaccharides, or a combination thereof. 
     
     
       4. The amphiphilic conjugate of  claim 3 , wherein the linker comprises consecutive polyethylene glycol units. 
     
     
       5. The amphiphilic conjugate of  claim 4 , wherein the linker comprises “N” consecutive polyethylene glycol units, wherein N is between 20 and 80. 
     
     
       6. The amphiphilic conjugate of  claim 5 , wherein the linker comprises 48 consecutive polyethylene glycol units. 
     
     
       7. An immunogenic composition comprising an amphiphilic conjugate of  claim 1 . 
     
     
       8. The immunogenic composition of  claim 7 , further comprising an adjuvant. 
     
     
       9. A pharmaceutical composition comprising a therapeutically effective amount of an immunogenic composition of  claim 7  and one or more pharmaceutically acceptable carriers or excipients.